TRLV vs USNA
Trulieve Cannabis Corp. and Usana Health Sciences, Inc., side by side — 7 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | TRLV | USNA |
|---|---|---|
| Revenue | $1.2B | $925.3M |
| Net income | $-122.2M | $10.8M |
| Gross margin | 60.2% | 78.3% |
| Net margin | −10.3% | 1.2% |
| Return on equity | — | 2.0% |
| Diluted EPS | −$0.58 | $0.58 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $228.6M | $8.5M |
| Equity | — | $533.1M |
| Net debt / equity | — | — |
| Current ratio | 4.43× | 2.24× |
| Revenue CAGR 5y | 17.8% | −4.0% |
| Profit CAGR 5y | — | −38.7% |
TRLV bills 1.3× the revenue of USNA, and TRLV closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
7 years side by side
| Fiscal year | TRLV | USNA |
|---|---|---|
| FY2025 | $1.2B | $925.3M |
| FY2024 | $1.2B | $854.5M |
| FY2023 | $1.1B | $921.0M |
| FY2022 | $1.2B | $998.6M |
| FY2021 | $931.9M | $1.2B |
| FY2020 | $521.5M | $1.1B |
| FY2019 | $252.8M | $1.1B |
Net income by year
Bottom line
| Fiscal year | TRLV | USNA |
|---|---|---|
| FY2025 | $-122.2M | $10.8M |
| FY2024 | $-160.6M | $42.0M |
| FY2023 | $-533.1M | $63.8M |
| FY2022 | $-252.7M | $69.3M |
| FY2021 | $17.4M | $116.5M |
| FY2020 | $63.0M | $124.7M |
| FY2019 | $53.1M | $100.5M |
Advertisement
AdSense · Rectangle 336×280
More in this industry